Description of Medical ServiceMicro-bypass glaucoma surgery (MBGS) devices describe a variety of ocular stents and scaffolds which, when placed in specific anatomical positions within the eye, aim to increase aqueous humour outflow, and reduce intraocular pressure. The proposed service describes the delivery of a MBGS stent which is pre-loaded on an inserter and implanted ab interno, via a corneal incision, into the trabecular meshwork or suprachoroidal space of the eye. The service is intended for individuals with primary open-angle glaucoma and is intended to be delivered as an independent procedure, not in conjunction with cataract surgery.
Description of Medical ConditionGlaucoma is a chronic degenerative optic neuropathy characterised by progressive visual field loss due to the loss of retinal ganglion cells and optic nerve damage. Primary open-angle glaucoma describes glaucoma in which disease is the primary disease of the eye with no associated conditions or diseases (primary) and the drainage channels for aqueous humour in the front of the eye appear open (open-angle.)
Reason for ApplicationNew MBS item
Medical Service TypeTherapeutic
Previous Application Number1483 and 1496
Public Summary DocumentPublic Summary Document (PDF 1238 KB)
Public Summary Document (Word 201 KB)
Meetings for this Application
ESC5 October 2018
MSAC22-23 November 2018
1-2 August 2019
Stakeholder MeetingMonday 4 March 2019, the Chair of MSAC, representatives of the applicants; clinicians with expertise in ophthalmology; a representative of a consumer organisation and representatives from the Department of Health met to discuss MBGS device implantation as a standalone procedure in patients with open-angle glaucoma. This was not an MSAC decision forum, but a meeting that would inform the issues considered by MSAC, following its November 2018 consideration of application 1541. The final minutes of this meeting are below.
Final Stakeholder Meeting Minutes (PDF 509 KB)
Final Stakeholder Meeting Minutes (Word 50 KB)